RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future

Overview

Journal Drugs

Specialty Pharmacology

Date 2024 Jul 12

PMID 38997570

Authors

Monica F Chen

Matteo Repetto

Clare Wilhelm

Alexander Drilon

Affiliations

Soon will be listed here.

Abstract

While activating RET fusions are identified in various cancers, lung cancer represents the most common RET fusion-positive tumor. The clinical drug development of RET inhibitors in RET fusion-positive lung cancers naturally began after RET fusions were first identified in patient tumor samples in 2011, and thereafter paralleled drug development in RET fusion-positive thyroid cancers. Multikinase inhibitors were initially tested with limited efficacy and substantial toxicity. RET inhibitors were then designed with improved selectivity, central nervous system penetrance, and activity against RET fusions and most RET mutations, including resistance mutations. Owing their success to these rationally designed features, the first-generation selective RET tyrosine kinase inhibitors (TKIs) had higher response rates, more durable disease control, and an improved safety profile compared to the multikinase inhibitors. This led to lung and thyroid cancer, and later tumor-agnostic regulatory approvals. While next-generation RET TKIs were designed to abrogate uncommon on-target (e.g., solvent front mutation) resistance to selpercatinib and pralsetinib, many of these drugs lacked the selectivity of the first-generation TKIs, raising the question of what the future holds for drug development in RET-dependent cancers.

References

Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J . Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene. 1995; 10(1):191-8. View

Chi X, Michos O, Shakya R, Riccio P, Enomoto H, Licht J . Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis. Dev Cell. 2009; 17(2):199-209. PMC: 2762206. DOI: 10.1016/j.devcel.2009.07.013. View

Drilon A, Hu Z, Lai G, Tan D . Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2017; 15(3):151-167. PMC: 7938338. DOI: 10.1038/nrclinonc.2017.175. View

Arighi E, Borrello M, Sariola H . RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005; 16(4-5):441-67. DOI: 10.1016/j.cytogfr.2005.05.010. View

Desilets A, Repetto M, Yang S, Sherman E, Drilon A . -Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity. Cancers (Basel). 2023; 15(16). PMC: 10452615. DOI: 10.3390/cancers15164146. View

Fitze G, Paditz E, Schlafke M, Kuhlisch E, Roesner D, Schackert H . Association of germline mutations and polymorphisms of the RET proto-oncogene with idiopathic congenital central hypoventilation syndrome in 33 patients. J Med Genet. 2003; 40(2):E10. PMC: 1735365. DOI: 10.1136/jmg.40.2.e10. View

Hwang D, Dworschak G, Kohl S, Saisawat P, Vivante A, Hilger A . Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract. Kidney Int. 2014; 85(6):1429-33. PMC: 4040148. DOI: 10.1038/ki.2013.508. View

Vega Q, Worby C, Lechner M, Dixon J, Dressler G . Glial cell line-derived neurotrophic factor activates the receptor tyrosine kinase RET and promotes kidney morphogenesis. Proc Natl Acad Sci U S A. 1996; 93(20):10657-61. PMC: 38210. DOI: 10.1073/pnas.93.20.10657. View

Milbrandt J, de Sauvage F, Fahrner T, Baloh R, Leitner M, Tansey M . Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron. 1998; 20(2):245-53. DOI: 10.1016/s0896-6273(00)80453-5. View

10.

Drilon A, Oxnard G, Tan D, Loong H, Johnson M, Gainor J . Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(9):813-824. PMC: 7506467. DOI: 10.1056/NEJMoa2005653. View

11.

Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M . Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18(3):382-4. PMC: 3916180. DOI: 10.1038/nm.2673. View

12.

Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik C, Tan D . Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; 33(11):1168-1178. DOI: 10.1016/j.annonc.2022.08.002. View

13.

Parimi V, Tolba K, Danziger N, Kuang Z, Sun D, Lin D . Genomic landscape of 891 RET fusions detected across diverse solid tumor types. NPJ Precis Oncol. 2023; 7(1):10. PMC: 9870857. DOI: 10.1038/s41698-023-00347-2. View

14.

Kato S, Subbiah V, Marchlik E, Elkin S, Carter J, Kurzrock R . Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2016; 23(8):1988-1997. DOI: 10.1158/1078-0432.CCR-16-1679. View

15.

Yang S, Aypar U, Rosen E, Mata D, Benayed R, Mullaney K . A Performance Comparison of Commonly Used Assays to Detect RET Fusions. Clin Cancer Res. 2020; 27(5):1316-1328. PMC: 8285056. DOI: 10.1158/1078-0432.CCR-20-3208. View

16.

Wang R, Hu H, Pan Y, Li Y, Ye T, Li C . RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012; 30(35):4352-9. DOI: 10.1200/JCO.2012.44.1477. View

17.

Cai W, Su C, Li X, Fan L, Zheng L, Fei K . KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer. 2013; 119(8):1486-94. DOI: 10.1002/cncr.27940. View

18.

Wang X . Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET. Biochim Biophys Acta. 2012; 1834(10):2205-12. DOI: 10.1016/j.bbapap.2012.10.008. View

19.

Hess L, Han Y, Zhu Y, Bhandari N, Sireci A . Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer. 2021; 21(1):28. PMC: 7786962. DOI: 10.1186/s12885-020-07714-3. View

20.

Drilon A, Lin J, Filleron T, Ni A, Milia J, Bergagnini I . Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. J Thorac Oncol. 2018; 13(10):1595-1601. PMC: 6434708. DOI: 10.1016/j.jtho.2018.07.004. View